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recombination. This possibility is sup-
ported by evidence that FANCD2 and 
FANCI are required for the homologous 
recombination induced by DNA double-
strand breaks (Moldovan and D’Andrea, 
2009), suggesting a general role of the 
FA pathway in promoting recombina-
tion. It is currently unclear whether this 
function represents a direct participa-
tion of the FA pathway (for example, 
recruitment of factors that mediate 
homologous recombination), or a more 
indirect one, such as inhibition of alter-
native competing repair pathways (such 
as the error-prone nonhomologous end-
joining pathway).
Despite these shortcomings, Xenopus 
egg extracts should allow the identifica-
tion and characterization of the nucle-
ases and polymerases involved in ICL 
repair and help to elucidate how these 
activities are controlled by the FA path-
way. This knowledge may, over time, 
lead to better therapeutic strategies for 
FA patients.
Together with the recently described 
role of the FA pathway in activating the 
DNA-damage checkpoint induced by 
crosslinks (Ben-Yehoyada et al., 2009), 
these new findings paint the picture 
of a dynamic, multifaceted pathway 
involved in numerous steps in the cellular 
response to DNA crosslinks.
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Sensations such as touch, temperature, 
itch, and pain are mediated by primary 
somatosensory neurons that detect 
thermal, mechanical, and chemical 
cues and relay this information to the 
central nervous system (Figure 1). Itch, 
or pruritus, is defined as the unpleas-
ant sensation that elicits scratching 
behavior. In this sense, itch is quite dis-
tinct from pain, the application of which 
causes the hasty withdrawal of the 
affected body part. Nevertheless, pain 
and itch stimuli can sometimes interact; 
for instance, a pain sensation can inhibit 
an itch sensation. It even has been sug-
gested that itch is a form of low-intensity 
pain. However, accumulating evidence 
favors the now prevailing view that pain 
and itch are reported by distinct primary 
sensory neurons and separate sensory 
pathways, albeit with overlapping regu-
latory mechanisms (Ikoma et al., 2006; 
Paus et al., 2006; Sun et al., 2009) So 
how is itch sensed? In this issue of Cell, 
a team of scientists led by Xinzhong 
Dong (Liu et al., 2009) provides evidence 
that some members of the Mrgpr family 
of seven-transmembrane G protein-
coupled receptors can mediate itch 
 sensation.
It is well established that some pri-
mary sensory neurons express members 
of a group of closely related receptors 
belonging to the Mrgpr family. There are 
?24 potentially functional Mrgpr genes in 
mice but, strikingly, only eight in humans 
(Dong et al., 2001). Mrgpr expression is 
highly restricted to primary sensory neu-
rons, hinting at a somatosensory role. 
However, their function has remained 
enigmatic. The new study by Liu et al. 
(2009) indicates that some of these recep-
tors are involved in an itch sensation that 
is independent of that mediated by the 
best known itch inducer, histamine.
Itching for Insight
Michael Bandell1 and Ardem Patapoutian1,2,*
1Genomics Institute of the Novartis Research Foundation, San Diego, CA 92121, USA
2Department of Cell Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
*Correspondence: apatapoutian@gnf.org
DOI 10.1016/j.cell.2009.12.012
The itch sensation results from the excitation of primary sensory nerve endings in the skin, but the 
underlying molecular mechanisms are not completely understood. Liu et al. (2009) now report that 
some members of the Mrgpr class of G protein-coupled receptors mediate the itch caused by the 
antimalarial drug chloroquine.
Cell 139, December 24, 2009 ©2009 Elsevier Inc. 1225
Histamine is the inflammatory mediator 
released by mast cells in response to a 
variety of external stimuli. Mosquito bites, 
for example, result in itching because mast 
cells are activated and release histamine, 
which then acts as a potent excitatory 
agent for itch neurons. Histamine acts via 
G protein-coupled histamine receptors 
present on sensory neurons (Ikoma et al., 
2006; Paus et al., 2006). Some pruritic 
conditions, however, appear to be inde-
pendent of histamine signaling. A well 
known example is the itch generated as a 
side effect of the antimalarial drug chloro-
quine; pruritus due to chloroquine can be 
so severe that patients sometimes stop 
treatment (Mnyika and Kihamia, 1991). 
Moreover, antihistamine drugs are inef-
fective in countering chloroquine-induced 
itch, indicating that an unknown mecha-
nism is at play (Abila et al., 1994).
This is where the study by Liu et al. 
(2009) comes in. The authors generated a 
mouse strain lacking a cluster of 12 Mrgpr 
genes (as well as ?18 Mrgpr pseudo-
genes) in their quest to identify the sensory 
function of these receptors. Deleting all of 
these genes at once was a smart move 
as there could be considerable functional 
overlap between the proteins encoded 
by these closely related genes. Strikingly, 
whereas mice lacking the Mrgpr gene 
cluster appear normal in their sensitivity 
to acute pain and histamine-induced itch, 
they show a dramatic (though not com-
plete) reduction in scratching behavior 
after chloroquine exposure. Thus Mrgprs 
appear to be required for chloroquine-
induced itch. But are they the actual 
receptors that sense chloroquine? The 
authors show that chloroquine excites a 
small subset of isolated sensory neurons, 
indicating that the drug interacts directly 
with sensory neurons (Figure 1). They fur-
ther show that chloroquine-induced exci-
tation is completely lost in mice lacking the 
Mrgpr cluster. The authors subsequently 
identify MrgprA3 as the major chloroquine 
receptor. Ectopic expression of MrgprA3 
in heterologous cells induces chloroquine 
sensitivity. The authors go on to show that 
MrgprA3 is necessary and sufficient for 
chloroquine-induced neuronal activation.
How do these findings translate to the 
human situation? Liu et al. (2009) take the 
first step by identifying a human Mrgpr 
receptor, MrgprX1, that also responds to 
chloroquine. MrgprX1 is significantly less 
sensitive to chloroquine than its murine 
counterpart. In fact, activation of this 
receptor required concentrations that 
exceed the chloroquine concentrations 
observed in plasma of patients under-
going chloroquine treatment. However, 
chloroquine accumulates at much higher 
levels in the skin where the MrgprX1 
receptor is located. Furthermore, there 
is considerable individual variability in 
chloroquine-induced itch that suggests 
a predisposing genetic factor. Notably, 
chloroquine-induced itch is very com-
mon among black Africans but less com-
mon among other races. Strikingly, Mrgpr 
genes are highly polymorphic, which sug-
gests the intriguing possibility that vari-
ability in MrgprX1 underlies the variabil-
ity in chloroquine itch. Clearly, whether 
MrgprX1 is responsible for chloroquine 
induced itch in the clinical setting requires 
further testing.
The new findings raise interesting ques-
tions. What are the roles of MrgprA3 and 
MrgprX1 beyond chloroquine-induced 
itch? Do they play a role in detecting other 
itch-inducing stimuli? Diverse disorders 
such as atopic dermatitis, chronic renal 
failure, chronic liver disease, lymphoma, 
and hyperthyroidism can result in chronic 
itch, a significant clinical problem (Ikoma 
et al., 2006). Does upregulation of endog-
enous molecules that signal via Mrgprs 
play a role? Mrgprs have the greatest 
sequence similarity to peptide hormone 
receptors, and Mrgprs are activated by 
neuropeptides. However, whether such 
peptides play a role in itch is currently not 
clear. Future research will undoubtedly 
address these questions, and provide 
insight on the therapeutic potential of 
Mrgpr modulators.
This new study also begs the question 
whether any other Mrgprs (in addition to 
MrgprA3 and MrgprX1) are involved in 
itch sensation. Liu et al. already report 
that MrgprC11 may be. This receptor is 
coexpressed with MrgprA3, and its acti-
vation causes scratching behavior in 
mice. As for the other Mrgprs, most are 
expressed in nonoverlapping subpopu-
lations of sensory neurons. MrgprD, for 
instance, appears to influence the excit-
ability of a subset of nociceptive neu-
rons that function in mechanosensation 
but not itch sensation (Cavanaugh et al., 
figure 1. two modes of Itch sensation
Peripheral itch sensation can be histamine dependent or histamine independent. Histamine, released 
from mast cells, acts on histamine receptors expressed by primary sensory neurons resulting in the 
itch sensation. However, there is a histamine-independent itch pathway that can be activated by the 
antimalarial drug chloroquine. Liu et al. (2009) now report that chloroquine acts largely through the 
mouse MrgprA3 and human MrgprX1 G protein-coupled receptors expressed by primary sensory 
neurons. Neurons within the dorsal root ganglion send projections to the skin. A primary sensory 
neuron expressing the histamine receptor is shown in yellow, and a neuron coexpressing histamine 
and MrgprA3 receptors is shown in red. Unmarked neurons transduce other sensory qualities such 
as innocuous and noxious thermal or mechanical information. (Some residual chloroquine induced 
itch is observed in mice lacking MrgprA3, which is attributed to indirect activation of itch neurons 
via mast cells.)
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2009; Rau et al., 2009). Furthermore, 
MrgprB4 is expressed in sensory neu-
rons that may detect gentle touch (Liu 
et al., 2007). Therefore, Mrgprs play 
important but apparently distinct roles 
in somatosensation. Still, the endog-
enous modulators of Mrgprs under 
physiological and pathophysiological 
conditions are largely unknown. Eluci-
dating relevant endogenous or exog-
enous ligands for this class of receptors 
will be an important future direction. 
The molecular pathways downstream of 
Mrgprs also remain to be unraveled.
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Cancer progression is traditionally viewed 
as a sequential tumorigenic process. 
Tumor cells at the primary sites gradually 
acquire the capacity to invade and intra-
vasate into the systemic circulation. These 
circulating tumor cells serve as conduits 
for the spread to distant organs. However, 
successful colonization at distant organs 
is dependent on acquisition of the ability 
of circulating tumor cells to leave circu-
lation (by extravasation) and to adapt to 
the new microenvironment (Chambers et 
al., 2002). Emerging evidence indicates 
that disseminated tumor cells are present 
in the circulation in large numbers even 
at early stages of cancer, long before 
metastatic growth at distant sites can be 
detected (Husemann et al., 2008). One 
recent study has demonstrated that even 
apparently untransformed mammary epi-
thelial cells can take residence at distant 
organs, such as the lung, for an extended 
period of time, and that later induction of 
transformation is sufficient to induce met-
astatic growth (Podsypanina et al., 2008). 
In this issue, Massagué and colleagues 
(Kim et al., 2009) add another twist to 
our understanding of tumor progression, 
showing that the flow of circulating tumor 
cells is not a one-way street—circulating 
cancer cells can reinfiltrate tumors at their 
organs of origin to promote the growth of 
the primary tumors (Figure 1).
The low rate of successful metastatic 
growth is at least in part due to rate-
limiting steps involving acquisition of the 
ability to extravasate and to adapt to new 
microenvironments. Massagué and col-
leagues reasoned that circulating tumor 
cells should require little adaptation to 
survive and grow at tumors from their 
primary organs. To test this hypothesis, 
the authors set up a clever tumor-seeding 
assay based on tumor xenograft mod-
els in mice. By implanting differentially 
labeled tumor xenografts at distinct ana-
tomical locations within the same mouse, 
they asked if tumor cells disseminated 
from one xenograft could home to the 
second xenograft over time. The authors 
found that metastatic tumor cells injected 
into the mammary fat pad, under the skin, 
or intravenously, or tumor cells shed from 
metastatic lesions, are readily detectable 
in a contralateral recipient xenograft after 
2 months. This tumor self-seeding phe-
nomenon is observed with tumor cells 
from breast, colon, and skin, suggesting 
that this is a general phenomenon in epi-
thelial tumors.
Massagué and colleagues further show 
that recipient tumors are preferentially 
seeded by highly metastatic derivatives 
from the tumor cell lines tested. In addi-
tion, these “seeder” cells colonize only to 
pre-existing tumors, not to the intact or 
tumor self-seeding:  
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Circulating tumor cells are responsible for seeding metastatic growth at distant sites. Kim et al. 
(2009) now discover that circulating tumor cells can reinfiltrate tumors at their primary organs and 
promote tumor progression.
